Telomir Pharma reports Telomir-1 kills pancreatic cancer cells in vitro; plans further studies

Telomir Pharmaceuticals, Inc.

Telomir-1 reduced survival of aggressive human pancreatic cancer (PANC-1) cells in concentration-dependent manner.
Effects partially reversed by iron re-addition, suggesting iron-dependent processes contribute to response.
Telomir-1 previously shown to influence tumor suppressor genes and iron-dependent histone demethylases relevant to pancreatic cancer.
Pancreatic cancer has five-year survival rate of ~12%; current treatments limited by toxicity and resistance.
Telomir plans to expand preclinical research to leukemia models and initiate in vivo validation studies for IND preparation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.